FIELD: medicine, pharmaceutics.
SUBSTANCE: water pharmaceutical preparative form contains, at least, one latrunculin, non-ionic surface-active substance and preparation for supporting tonicity, at pH from 4 to 8. Latrunkulin, surface-active substance and preparation for supporting tonicity are compatible in preparative form, and preparative form does not contain more than 0.1% vol/vol dimethylsulfoxide. Latrunculin represents latrunculin A, latrunculin B, desmethyl latrunculin B or latrunculin analogue. Non-ionic surface-active substance is polysorbate, poloxamer or their combination. In accordance with the second version, water pharmaceutical form contains latrunculin, ethanol and preparation for supporting tonicity. Preparative form is intended for reduction of intraocular pressure in mammals. Preparative form by invention is stable during, at least, six months when cooled.
EFFECT: preparative form is intended for reduction of intraocular pressure in mammals.
15 cl, 5 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS USED FOR DECREASING OCULAR HYPERTENSION | 1998 |
|
RU2197970C2 |
| CONCENTRATED PROTEIN PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION | 2011 |
|
RU2626512C2 |
| DRUG FORM FOR hGH AND rhIGF-1 COMBINATION+ | 2010 |
|
RU2558821C2 |
| SUSPENSIONS OF NANOPARTICLES, CONTAINING CARBOXYVINYL POLYMER | 2010 |
|
RU2571078C2 |
| PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING DRY-EYE SYNDROME | 2008 |
|
RU2445098C2 |
| CYTOSKELETON-ACTIVE COMPOUNDS, COMPOSITIONS AND USE | 2006 |
|
RU2407745C2 |
| STABLE PHARMACEUTICAL COMPOSITION, INCLUDING REDUCED COMPOSITION OF PULMONARY SURFACTANT | 2017 |
|
RU2748417C2 |
| LOW-DOSE BRIMONIDINE COMBINATIONS AND THEIR USE | 2018 |
|
RU2801221C2 |
| COMPOSITIONS CONTAINING ANAKINRA | 2016 |
|
RU2728795C2 |
| PROPOFOL STABLE CLEAR COMPOSITIONS | 2001 |
|
RU2257892C2 |
